Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-25 20:05 | 2026-03-23 | VCEL | Vericel Corp | Hagen Heidi | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $32.41 | 15,000 | $486,150 | 31,850 | -32.0% |
| 2026-03-05 00:05 | 2026-03-02 | VCEL | Vericel Corp | Flynn Sean C. | Officer; Chief Legal Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $35.18 | 21,421 | $753,531 | 1,262 | -94.4% |
| 2026-03-05 00:05 | 2026-03-02 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | SALE | $35.30 | 10,305 | $363,767 | 16,080 | -39.1% |
| 2026-02-14 00:05 | 2026-02-11 | VCEL | Vericel Corp | MCLAUGHLIN KEVIN F | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $34.66 | 7,000 | $242,620 | 15,100 | -31.7% |
| 2026-01-10 00:05 | 2026-01-07 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $40.48 | 10,000 | $404,800 | 16,080 | -38.3% |
| 2025-12-05 00:05 | 2025-12-02 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $39.14 | 1,652 | $64,659 | 66,562 | -2.4% |
| 2025-12-05 00:05 | 2025-12-02 | VCEL | Vericel Corp | Wotton Paul K | Director | Biological Products, (No Diagnostic Substances) | SALE | $37.90 | 5,000 | $189,500 | 25,602 | -16.3% |
| 2025-11-14 00:05 | 2025-11-11 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $40.41 | 2,642 | $106,763 | 15,932 | -14.2% |
| 2025-11-13 00:06 | 2025-11-10 | VCEL | Vericel Corp | MCLAUGHLIN KEVIN F | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $38.59 | 7,000 | $270,130 | 15,100 | -31.7% |
| 2025-11-11 00:05 | 2025-11-06 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $40.47 | 7,358 | $297,778 | 15,932 | -31.6% |
| 2025-09-03 23:06 | 2025-09-02 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $35.77 | 10,000 | $357,700 | 66,363 | -13.1% |
| 2025-08-08 23:05 | 2025-08-06 | VCEL | Vericel Corp | MCLAUGHLIN KEVIN F | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $35.92 | 7,000 | $251,440 | 15,100 | -31.7% |
| 2025-06-04 23:05 | 2025-06-02 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $40.09 | 10,000 | $400,900 | 66,237 | -13.1% |
| 2025-05-16 23:06 | 2025-05-14 | VCEL | Vericel Corp | Colangelo Dominick | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $41.89 | 28,125 | $1,178,156 | 260,354 | -9.7% |
| 2025-05-09 23:05 | 2025-05-07 | VCEL | Vericel Corp | MCLAUGHLIN KEVIN F | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $39.98 | 7,000 | $279,860 | 15,100 | -31.7% |
| 2025-04-11 23:05 | 2025-04-09 | VCEL | Vericel Corp | Colangelo Dominick | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $41.50 | 49,700 | $2,062,550 | 260,354 | -16.0% |
| 2025-03-14 23:07 | 2025-03-12 | VCEL | Vericel Corp | Colangelo Dominick | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $46.05 | 53,183 | $2,448,811 | 259,997 | -17.0% |
| 2025-03-06 00:05 | 2025-03-03 | VCEL | Vericel Corp | Mara Joseph Anthony Jr | Officer; Chief Financial Officer | Biological Products, (No Diagnostic Substances) | SALE | $49.53 | 9,000 | $445,770 | 13,967 | -39.2% |
| 2025-03-06 00:05 | 2025-03-03 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $49.52 | 10,000 | $495,200 | 15,539 | -39.2% |
| 2025-03-06 00:05 | 2025-03-03 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $49.53 | 10,000 | $495,300 | 66,101 | -13.1% |
| 2025-03-06 00:05 | 2025-03-03 | VCEL | Vericel Corp | Hagen Heidi | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $49.53 | 9,000 | $445,770 | 28,650 | -23.9% |
| 2025-02-27 00:05 | 2025-02-25 | VCEL | Vericel Corp | SIEGAL JONATHAN | Officer; Principal Accounting Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $52.07 | 1,137 | $59,204 | 1,206 | -48.5% |
| 2025-02-27 00:05 | 2025-02-25 | VCEL | Vericel Corp | Flynn Sean C. | Officer; Chief Legal Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $52.07 | 1,669 | $86,905 | 756 | -68.8% |
| 2025-02-25 00:05 | 2025-02-20 | VCEL | Vericel Corp | Flynn Sean C. | Officer; Chief Legal Officer | Biological Products, (No Diagnostic Substances) | SALE | $57.32 | 3,835 | $219,822 | 756 | -83.5% |
| 2025-02-21 00:05 | 2025-02-19 | VCEL | Vericel Corp | SIEGAL JONATHAN | Officer; Principal Accounting Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $56.72 | 1,710 | $96,991 | 1,206 | -58.6% |
| 2025-02-15 00:05 | 2025-02-12 | VCEL | Vericel Corp | MCLAUGHLIN KEVIN F | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $55.46 | 7,000 | $388,250 | 11,900 | -37.0% |
| 2025-02-08 00:12 | 2025-02-05 | VCEL | Vericel Corp | SIEGAL JONATHAN | Officer; Principal Accounting Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $61.99 | 1,092 | $67,693 | 1,206 | -47.5% |
| 2025-02-08 00:18 | 2025-02-05 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $62.50 | 2,500 | $156,250 | 26,595 | -8.6% |
| 2025-01-31 00:05 | 2025-01-28 | VCEL | Vericel Corp | SIEGAL JONATHAN | Officer; Principal Accounting Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $61.99 | 3,908 | $242,257 | 1,206 | -76.4% |
| 2024-12-06 00:05 | 2024-12-04 | VCEL | Vericel Corp | Wotton Paul K | Director | Biological Products, (No Diagnostic Substances) | SALE | $58.72 | 2,600 | $152,672 | 27,402 | -8.7% |
| 2024-12-04 00:05 | 2024-12-02 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $58.72 | 10,000 | $587,200 | 58,371 | -14.6% |
| 2024-11-26 00:05 | 2024-11-22 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $60.00 | 2,500 | $150,000 | 26,595 | -8.6% |
| 2024-11-16 00:05 | 2024-11-13 | VCEL | Vericel Corp | Colangelo Dominick | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $54.75 | 35,000 | $1,916,250 | 220,937 | -13.7% |
| 2024-11-16 00:05 | 2024-11-13 | VCEL | Vericel Corp | MCLAUGHLIN KEVIN F | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $55.54 | 7,000 | $388,780 | 11,900 | -37.0% |
| 2024-11-14 00:05 | 2024-11-11 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $56.25 | 5,000 | $281,250 | 26,595 | -15.8% |
| 2024-10-18 23:05 | 2024-10-16 | VCEL | Vericel Corp | GILMAN STEVEN C | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $41.36 | 5,833 | $241,253 | 11,000 | -34.7% |
| 2024-10-18 23:05 | 2024-10-16 | VCEL | Vericel Corp | Colangelo Dominick | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $40.86 | 35,000 | $1,430,100 | 220,937 | -13.7% |
| 2024-10-04 23:06 | 2024-10-02 | VCEL | Vericel Corp | GILMAN STEVEN C | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $40.35 | 5,833 | $235,362 | 11,000 | -34.7% |
| 2024-10-02 23:06 | 2024-10-01 | VCEL | Vericel Corp | SIEGAL JONATHAN | Officer; Principal Accounting Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $41.90 | 568 | $23,799 | 1,124 | -33.6% |
| 2024-09-20 23:05 | 2024-09-18 | VCEL | Vericel Corp | GILMAN STEVEN C | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $45.54 | 5,834 | $265,680 | 11,000 | -34.7% |
| 2024-09-13 23:05 | 2024-09-11 | VCEL | Vericel Corp | Colangelo Dominick | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $43.64 | 35,000 | $1,527,225 | 220,937 | -13.7% |
| 2024-09-05 23:05 | 2024-09-03 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $49.83 | 10,000 | $498,300 | 58,229 | -14.7% |
| 2024-09-05 23:06 | 2024-09-04 | VCEL | Vericel Corp | GILMAN STEVEN C | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $48.58 | 5,000 | $242,900 | 11,000 | -31.3% |
| 2024-08-16 23:05 | 2024-08-14 | VCEL | Vericel Corp | Colangelo Dominick | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $45.71 | 35,000 | $1,599,675 | 220,937 | -13.7% |
| 2024-08-09 23:05 | 2024-08-07 | VCEL | Vericel Corp | MCLAUGHLIN KEVIN F | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $45.94 | 7,000 | $321,580 | 11,900 | -37.0% |
| 2024-07-19 23:05 | 2024-07-17 | VCEL | Vericel Corp | Colangelo Dominick | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $51.48 | 35,000 | $1,801,625 | 220,937 | -13.7% |
| 2024-07-18 23:05 | 2024-07-16 | VCEL | Vericel Corp | Flynn Sean C. | Officer; Chief Legal Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $52.18 | 15,000 | $782,700 | 707 | -95.5% |
| 2024-07-16 23:05 | 2024-07-12 | VCEL | Vericel Corp | Mara Joseph Anthony Jr | Officer; Chief Financial Officer | Biological Products, (No Diagnostic Substances) | SALE | $50.00 | 5,000 | $250,000 | 14,436 | -25.7% |
| 2024-07-09 23:05 | 2024-07-05 | VCEL | Vericel Corp | SIEGAL JONATHAN | Officer; Principal Accounting Officer | Biological Products, (No Diagnostic Substances) | SALE | $45.00 | 545 | $24,525 | 1,033 | -34.5% |
| 2024-06-25 01:21 | 2024-06-20 | VCEL | Vericel Corp | Flynn Sean C. | Officer; Chief Legal Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $45.11 | 15,000 | $676,644 | 487 | -96.9% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.